As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of ixekizumab in the treatment of psoriatic arthritis and ankylosing spondylitis.
This review discusses its pharmacological properties, dosage and administration, efficacy and tolerability, and evidence in support of the use of xekizumab as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Professor Peter Nash, Professor in the School of Medicine at Griffith University, Queensland, and Director of the Rheumatology Research Unit on the Sunshine Coast.
Please login below to download this issue (PDF)